10:30 AM EST - Marvel Biosciences Corp : Announces that in a pre-clinical test for anxiety, its lead drug candidate MB-204, a fluorinated derivative of Istradefylline, out-performed Istradefylline in a head-to-head pre-clinical and in depressive and anti-anxiety studies. Istradefylline is the only US FDA approved A2a receptor antagonist currently approved to treat Parkinson's disease. Marvel Biosciences Corp
shares V.MRVL are trading up 4.3% at $0.12.
